MicroRNAs (miRNAs) are emerging as central players in cancer progression. Aberrant expression of miRNAs leads to malignant transformation and correlates with staging, progression and prognosis of cancers. Unfortunately, signaling pathways leading to altered expression of miRNAs are largely unknown. During early development of colon cancer, the expression of cyclooxygenase 2 (COX-2) is constitutively induced. We and others have shown that constitutive expression of COX-2 promotes colon carcinogenesis. However, the underlying mechanisms are not completely understood. To determine if COX-2 signaling alters expression of miRNAs, we used the Human Cancer RT2-miRNA PCR arrays to profile miRNA expression in HCA-7 human colon cancer cells treated with or without the COX-2 selective inhibitor NS-398. HCA-7 cells constitutively express endogenous COX-2. We found that expression levels of 39 miRNAs are different in HCA-7 cells as compared to HCA-7 cells treated with NS-398; 8 miRNAs were up-regulated and 31 miRNAs were down-regulated. To confirm the data from the PCR array, we used quantitative RT-PCR to quantify expression of 8 miRNAs in HCA-7 cells with or without NS-398 treatment. These 8 miRNAs were selected due to their relevance to cancer invasion and metastasis. We also compared the expression of these miRNAs in HCT-15 human colon cancer cells that were engineered to stably express COX-2 (HCT-15-COX-2) to the parental HCT-15 cells. Expression levels of 6 of the 8 examined miRNAs (miR-23b, 124, 146b-5p, 155, 183, 184) were significantly lower in HCT-15-COX-2 or HCA-7 cells than in parental HCT-15 or HCA-7 cells that were treated with NS-398. Therefore, we identified 6 miRNAs that are modulated by COX-2 and may play a role in mediating COX-2 signaling to promote colon carcinogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3042.
During early development of colon cancer, cyclooxygenase 2 (COX‐2) is constitutively induced. Constitutive expression of COX‐2 promotes colon carcinogenesis, however the underlying mechanisms are not totally understood. Western blot analysis showed reduced protein levels of an adhesion molecule α‐catenin in HCA‐7 colon cancer cells that endogenously express COX‐2 and HCT‐15 colon cancer cells that stably express recombinant COX‐2 (HCT‐15‐COX‐2). High levels of phosphorylated active ERKs were also detected in HCA‐7 and HCT‐15‐COX‐2 cells. Inhibition of COX‐2 stimulated α‐catenin levels and prevented activation of ERKs. Scratch wound gap assays were used to monitor cell motility and proliferation. HCT‐15‐COX‐2 cells closed the gap faster than parental HCT‐15 cells. Inhibition of COX‐2 or ERKs in HCA‐7 and HCT‐15‐COX‐2 cells decreased the gap closing. The Human Cancer RT2‐miRNA PCR array screening showed that 39 microRNAs (miRNAs) are modulated by COX‐2 signaling. Quantitative RT‐PCR confirmed that expression levels of 6 miRNAs were significantly lower in HCA‐7 or HCT‐15‐COX‐2 than in HCA‐7 cells that were treated with the COX‐2‐selecetive inhibitor NS‐398 or HCT‐15 parental cells. Those 6 miRNAs were selected due to their relevance to cancer cell migration. In summary, we have identified that activation of ERKs and modulation of miRNAs mediate COX‐2 signaling to promote colon carcinogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.